Keyphrases
Mantle Cell Lymphoma
100%
Overall Survival
54%
Confidence Interval
45%
Young Patients
40%
Rituximab Era
40%
Nivolumab
40%
Progression-free Survival
38%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
32%
Survival Outcomes
25%
Blastoids
25%
Hazard Ratio
23%
Non-associated
22%
Practice Outcomes
20%
Practice Patterns
20%
Improved Survival
20%
Lymphoma Patients
20%
Early Relapse
20%
Practice Analysis
20%
Maintenance Rituximab
20%
Frontline Therapy
20%
Induction Regimen
20%
Cardiotoxicity Screening
20%
Older Patients
20%
Initial Treatment
20%
Imaging Methods
20%
Aurora Kinase Inhibitor
20%
Relapse Risk
20%
Favorable Risk
20%
Small Cell Lung Cancer
20%
Appendiceal Cancer
20%
Small Cell Lung Carcinoma
20%
Adjuvant Chemotherapy
20%
Chemotherapy-induced Cardiotoxicity
20%
Leukemia Patients
20%
HiDAC
20%
Acute Myeloid Leukemia
20%
Intermediate-dose Cytarabine
20%
Radiation Exposure
20%
Cardiac Imaging
20%
Cancer Cases
20%
High Risk
20%
Prolonged Response
20%
Pleomorphic Variant
20%
Recurrent Pleural Effusion
20%
Pseudoprogression
20%
Cardiac Tamponade
20%
Effusion
20%
Retrospective multicenter Study
20%
High-dose Cytarabine
19%
Overall Survival Rate
15%
Medicine and Dentistry
Mantle Cell Lymphoma
80%
Overall Survival
63%
Progression Free Survival
40%
Nivolumab
40%
Rituximab
40%
Cytarabine
29%
Hazard Ratio
27%
Malignant Neoplasm
25%
Acute Myeloid Leukemia
20%
Cell Transplantation
20%
Small Cell Lung Cancer
20%
Phosphotransferase Inhibitor
20%
Radiation Exposure
20%
Cardiac Imaging
20%
Pleura Effusion
20%
Effusion
20%
Cardiotoxicity
20%
Aurora A Kinase
20%
Adjuvant Chemotherapy
20%
Tamponade
20%
Hematopoietic Cell
20%
Drug Megadose
14%
Neoplasm
12%
Intensive Care
12%
Survival Rate
11%
Tumor
10%
Adenocarcinoma
10%
Disease Course
9%
Diseases
9%
Mantle Cell Lymphoma International Prognostic Index
8%
Multigene Family
8%
Cardiac Magnetic Resonance Imaging
8%
Echocardiography
8%
Proportional Hazards Model
6%
Univariate Analysis
5%
Multivariate Analysis
5%
Lung Cancer
5%
Case Presentation
5%
Cancer
5%
Pericardiocentesis
5%
Clinical Trial
5%
Pericardial Fluid
5%
